| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.6M | +0.8% | -27.8% |
| SG&A Expense | $1.2M | +1.4% | -16.8% |
| Operating Income | -$2.7M | -1.0% | +23.4% |
| Net Income | -$2.7M | -5.3% | +24.0% |
| EPS (Basic) | -$0.06 | +53.8% | +76.0% |
| EPS (Diluted) | -$0.06 | +53.8% | +76.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.1M | +218.9% | +154.0% |
| Current Assets | $8.2M | +169.5% | +116.2% |
| Total Assets | $9.6M | +115.7% | +83.9% |
| Current Liabilities | $2.3M | +5.2% | -1.8% |
| Total Liabilities | $2.4M | +4.6% | -2.9% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.8M | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $11.3M | — | — |
| $7.2M |
| +230.7% |
| +159.9% |